Evan Swanson, MD
Family Medicine · Ottawa, KSNPI 1144223066
Payments from drug & device makers
Across 94 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$313
- Smith+Nephew$287
- Medline Industries LP$145
- AbbVie$140
- Organogenesis Inc.$111
- Tactile Systems Technology Inc$108
- plus $452 from 17 others
What the payments were for
- Food & beverage$1,556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 13 | $313 |
| Smith+Nephew | 26 | $287 |
| Medline Industries LP | 5 | $145 |
| AbbVie(2 entities) | 8 | $140 |
| Organogenesis Inc. | 6 | $111 |
| Tactile Systems Technology Inc | 6 | $108 |
| Sunovion Pharmaceuticals Inc. | 11 | $85 |
| Convatec Inc. | 4 | $82 |
| Hydrofera LLC | 1 | $30 |
| AstraZeneca | 1 | $26 |
| KCI USA, Inc. | 1 | $25 |
| Electronic Waveform Lab, Inc. | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $21 |
| Imbed Biosciences Inc. | 1 | $21 |
| Kerecis Limited | 1 | $19 |
| Urgo Medical North America, LLC | 1 | $19 |
| Next Science LLC | 1 | $17 |
| Merck | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Molnlycke Health Care US, LLC | 1 | $11 |
| Reprise Biomedical, Inc. | 1 | $10 |
How this compares
$1,556 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 25 | $384 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $252 |
| Gabapentin | 27 | $208 |
| Fluconazole | 22 | $151 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $150 |
| Nystatin | 16 | $136 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $112 |
| Cephalexin | 12 | $88 |
| Levofloxacin | 11 | $65 |
| Prednisone | 19 | $53 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Ottawa
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.